Nouri Neamati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nouri Neamati has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
Mats Ljungman
Department of Radiation Oncology, Rogel Cancer Center, and Center for RNA Biomedicine
16 shared publicationsArmita Kyani
Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, North Campus Research Complex, 1600 Huron Parkway, Ann Arbor, Michigan 48109, United States
10 shared publicationsBikash Debnath
Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center
10 shared publications- Andrii Balia
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan
9 shared publications - Cristina Castillo
Department of Molecular & Physiology, University of Michigan, Ann Arbor, MI, USA
9 shared publications - Elizabeth C. McCulla
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
9 shared publications
Latest Publications
- Open Access
S100A9-Dependent CXCR2 hi Neutrophils Mediate Systemic Immune Suppression and Checkpoint Resistance in Metastatic TNBC
Most high-dimensional studies of tumor-immune interactions focus on metastatic models, limiting insight into how immune remodeling in primary tumors shapes metastatic competence. Here, integrating single-cell RNA sequencing, CyTOF, and functional studies across metastatic (4T1) and non-invasive (EMT6) triple-negative breast cancer (TNBC) murine models, we define tumor state-specific immune programs that distinguish metastatic competence. Tumors with metastatic capacity uniquely drive early bone marrow expansion of CXCR2⁺ neutrophils, which infiltrate primary tumors acquiring a CXCL2-producing phenotype that promotes EMT-associated cancer stem cell (CSC) plasticity. This program depends on TGF-β/CEBPD-mediated induction of S100A9. Elevated CXCL2, together with G-CSF, establishes a feed-forward circuit that drives systemic neutrophil mobilization and recruitment to distant organs, where neutrophil-derived S100A8/A9 (calprotectin) promotes MET-driven CSC outgrowth and metastatic colonization. Clinically, gene signatures associated with CXCR2⁺ neutrophils predict poor survival in TNBC patients, whereas monocyte/macrophage (CX3CR1⁺) and T cell activation signatures correlate with improved outcomes. S100A9 ablation disrupts this cascade and enhances immunotherapy responsiveness, defining a TGF-β/S100A9/CXCR2 axis linking immune remodeling, CSC plasticity and metastasis. Highlights: Metastatic TNBC engages a TGF-β/C/EBPδ/S100A9 axis that expands CXCR2⁺ neutrophils Non-invasive EMT6 tumors retain a CX3CR1⁺ monocyte/macrophage and T-cell landscape CXCR2 + neutrophils in pre-metastatic niches suppress T cell response while promoting tumor cell proliferation S100A9 loss redirects myelopoiesis and potentiates anti-PD-L1 in TNBC models In Brief: Alkan et al. dissect how tumor state programs the myeloid compartment in TNBC. Metastatic 4T1 tumors uniquely engage a TGF-β/C/EBPδ/S100A9 axis driving CXCR2⁺ neutrophil expansion and CXCL2/G-CSF-dependent systemic mobilization, coupling immune remodeling to EMT/MET cancer-stem-cell plasticity, while S100A9 loss restores CX3CR1⁺ myeloid identity and unlocks checkpoint-inhibitor responsiveness.
Open AccessS100A9-Dependent CXCR2 hi Neutrophils Mediate Systemic Immune Suppression and Checkpoint Resistance in Metastatic TNBC
Most high-dimensional studies of tumor-immune interactions focus on metastatic models, limiting insight into how immune remodeling in primary tumors shapes metastatic competence. Here, integrating single-cell RNA sequencing, CyTOF, and functional studies across metastatic (4T1) and non-invasive (EMT6) triple-negative breast cancer (TNBC) murine models, we define tumor state-specific immune programs that distinguish metastatic competence. Tumors with metastatic capacity uniquely drive early bone marrow expansion of CXCR2⁺ neutrophils, which infiltrate primary tumors acquiring a CXCL2-producing phenotype that promotes EMT-associated cancer stem cell (CSC) plasticity. This program depends on TGF-β/CEBPD-mediated induction of S100A9. Elevated CXCL2, together with G-CSF, establishes a feed-forward circuit that drives systemic neutrophil mobilization and recruitment to distant organs, where neutrophil-derived S100A8/A9 (calprotectin) promotes MET-driven CSC outgrowth and metastatic colonization. Clinically, gene signatures associated with CXCR2⁺ neutrophils predict poor survival in TNBC patients, whereas monocyte/macrophage (CX3CR1⁺) and T cell activation signatures correlate with improved outcomes. S100A9 ablation disrupts this cascade and enhances immunotherapy responsiveness, defining a TGF-β/S100A9/CXCR2 axis linking immune remodeling, CSC plasticity and metastasis. Highlights: Metastatic TNBC engages a TGF-β/C/EBPδ/S100A9 axis that expands CXCR2⁺ neutrophils Non-invasive EMT6 tumors retain a CX3CR1⁺ monocyte/macrophage and T-cell landscape CXCR2 + neutrophils in pre-metastatic niches suppress T cell response while promoting tumor cell proliferation S100A9 loss redirects myelopoiesis and potentiates anti-PD-L1 in TNBC models In Brief: Alkan et al. dissect how tumor state programs the myeloid compartment in TNBC. Metastatic 4T1 tumors uniquely engage a TGF-β/C/EBPδ/S100A9 axis driving CXCR2⁺ neutrophil expansion and CXCL2/G-CSF-dependent systemic mobilization, coupling immune remodeling to EMT/MET cancer-stem-cell plasticity, while S100A9 loss restores CX3CR1⁺ myeloid identity and unlocks checkpoint-inhibitor responsiveness.
- 9 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14020-14039
Beyond Target Occupancy in Triple-Negative Breast Cancer: A Medicinal Chemistry Perspective on Modality-Guided Design for Durable Network Control
Triple-negative breast cancer (TNBC) remains difficult to treat because durable response is rarely achieved with conventional occupancy-driven inhibition. The central challenge is not simply a lack of actionable targets but a mismatch between TNBC's adaptive network biology and the limited depth of reversible node-by-node intervention. In this Perspective, we argue that the key medicinal chemistry question is not only which protein to engage, but which chemical modality best matches a given biological liability. We focus on metabolic coupling, epigenetic scaffold dependence, immune-stromal exclusion, and DNA damage response plasticity and discuss how these vulnerabilities motivate targeted degradation, molecular glues, covalent inhibition, rational polypharmacology, or prodrug design. Across these modalities, ternary-complex productivity, linker topology, warhead presentation, isoform selectivity, exposure control, and postwashout persistence often matter more than potency alone. Biological vulnerability defines the design problem, chemical modality defines the intervention logic, and durable network control defines success.
- 9 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (12) , 14020-14039
Beyond Target Occupancy in Triple-Negative Breast Cancer: A Medicinal Chemistry Perspective on Modality-Guided Design for Durable Network Control
Triple-negative breast cancer (TNBC) remains difficult to treat because durable response is rarely achieved with conventional occupancy-driven inhibition. The central challenge is not simply a lack of actionable targets but a mismatch between TNBC's adaptive network biology and the limited depth of reversible node-by-node intervention. In this Perspective, we argue that the key medicinal chemistry question is not only which protein to engage, but which chemical modality best matches a given biological liability. We focus on metabolic coupling, epigenetic scaffold dependence, immune-stromal exclusion, and DNA damage response plasticity and discuss how these vulnerabilities motivate targeted degradation, molecular glues, covalent inhibition, rational polypharmacology, or prodrug design. Across these modalities, ternary-complex productivity, linker topology, warhead presentation, isoform selectivity, exposure control, and postwashout persistence often matter more than potency alone. Biological vulnerability defines the design problem, chemical modality defines the intervention logic, and durable network control defines success.
- Open Access
- 16 March 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (4) , 784-814
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
The ubiquitin-proteasome system (UPS) comprises an important cellular process that regulates protein homeostasis by selectively degrading misfolded or damaged proteins, as well as those with short half-lives. Proteins are targeted for proteasomal degradation via a multistep cascade of E1-E2-E3 enzymes that catalyze the polyubiquitination of substrate proteins, which can be recognized by the proteasome and degraded into smaller peptides. Targeted protein degradation is a technology that takes advantage of the UPS for selectively channeling proteins of interest (POI) for proteasomal degradation using compounds that facilitate the interaction of an E3 ligase with the POI as a neo-substrate. This review focuses on the main principles of designing proteolysis-targeting chimeras (PROTACs). The advantages and limitations of PROTAC use as a research tool in the laboratory or as novel therapeutics in clinical trials are also discussed. Initially described in 2001, PROTACs have since revolutionized the drug discovery field and comprise a novel therapeutic modality that expands the druggable proteome via a unique mechanism of action. More than 30 PROTACs have entered clinical trials, and early clinical success of PROTACs targeting well-characterized disease drivers inspired the field to move toward targeting proteins that were previously considered “undruggable” with conventional drug design, such as transcription factors. Over the last two decades since its discovery, the PROTAC technology has gained tremendous excitement in both basic research and drug discovery and could soon become a key therapeutic modality. PROTACs can potentially make a significant impact on the survival and quality of life of patients suffering from different diseases.
- 16 March 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (4) , 784-814
Open AccessMechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
The ubiquitin-proteasome system (UPS) comprises an important cellular process that regulates protein homeostasis by selectively degrading misfolded or damaged proteins, as well as those with short half-lives. Proteins are targeted for proteasomal degradation via a multistep cascade of E1-E2-E3 enzymes that catalyze the polyubiquitination of substrate proteins, which can be recognized by the proteasome and degraded into smaller peptides. Targeted protein degradation is a technology that takes advantage of the UPS for selectively channeling proteins of interest (POI) for proteasomal degradation using compounds that facilitate the interaction of an E3 ligase with the POI as a neo-substrate. This review focuses on the main principles of designing proteolysis-targeting chimeras (PROTACs). The advantages and limitations of PROTAC use as a research tool in the laboratory or as novel therapeutics in clinical trials are also discussed. Initially described in 2001, PROTACs have since revolutionized the drug discovery field and comprise a novel therapeutic modality that expands the druggable proteome via a unique mechanism of action. More than 30 PROTACs have entered clinical trials, and early clinical success of PROTACs targeting well-characterized disease drivers inspired the field to move toward targeting proteins that were previously considered “undruggable” with conventional drug design, such as transcription factors. Over the last two decades since its discovery, the PROTAC technology has gained tremendous excitement in both basic research and drug discovery and could soon become a key therapeutic modality. PROTACs can potentially make a significant impact on the survival and quality of life of patients suffering from different diseases.
- 13 March 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (4) , 902-924
Copper Transporter 1-Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors
Certain tumors are dependent on copper for proliferation, metastasis, and energy production, making them particularly susceptible to copper depletion. Altering copper homeostasis has emerged as a promising strategy for treating these cancers. Previously, we synthesized novel compounds, JR4-187 (JR4) and JR5-26B (JR5), which demonstrated copper-dependent in vivo efficacy. RNA-seq analysis revealed that JR4 treatment in colon cancer cells leads to a marked downregulation of oxidative phosphorylation and MYC-targeted genes. Both JR4 and JR5 reduce MYC and NDUFS7 protein levels. Additionally, JR4 and JR5 increase tumor cell sensitivity to complex I inhibitors, including AGB-374, a novel NDUFS7 inhibitor that we developed. AGB-374 exhibited in vivo efficacy when administered orally, both as a single agent and in combination with JR5, in a mouse model of colon cancer. Our findings indicate a significant functional relationship between CTR1 and NDUFS7, providing a foundation for the development of new cancer therapies.
- 13 March 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (4) , 902-924
Copper Transporter 1-Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors
Certain tumors are dependent on copper for proliferation, metastasis, and energy production, making them particularly susceptible to copper depletion. Altering copper homeostasis has emerged as a promising strategy for treating these cancers. Previously, we synthesized novel compounds, JR4-187 (JR4) and JR5-26B (JR5), which demonstrated copper-dependent in vivo efficacy. RNA-seq analysis revealed that JR4 treatment in colon cancer cells leads to a marked downregulation of oxidative phosphorylation and MYC-targeted genes. Both JR4 and JR5 reduce MYC and NDUFS7 protein levels. Additionally, JR4 and JR5 increase tumor cell sensitivity to complex I inhibitors, including AGB-374, a novel NDUFS7 inhibitor that we developed. AGB-374 exhibited in vivo efficacy when administered orally, both as a single agent and in combination with JR5, in a mouse model of colon cancer. Our findings indicate a significant functional relationship between CTR1 and NDUFS7, providing a foundation for the development of new cancer therapies.
- 5 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1951-1969
Dioscin Suppresses Ovarian and Gastric Tumor Progression by Inhibiting ALDH1A3 ‐Mediated Retinoic Acid Metabolism and Cancer Stemness
Background: ALDH1A3 is a key factor associated with tumor stemness and chemotherapy resistance, making it a promising therapeutic target. Screening various compounds with potential inhibition of cancer stem cells led to the discovery of a naturally occurring Dioscin as a novel ALDH1A3 inhibitor. However, the precise mechanism underlying its action remains unexplored. Experimental Procedure: Immunohistochemical analysis of 90 ovarian serous tumor samples revealed the clinical significance of ALDH1A3 in tumor progression. TCGA data was used to identify genes highly correlated with ALDH1A3 in ovarian cancer. Using CRISPR/Cas9‐generated ALDH1A3 knockout (KO) cell lines, we investigated its oncogenic influence in ovarian and gastric cancers. The anti‐tumor effects of Dioscin were assessed through MTT, scratch, and 3D spheroid formation assays. In vivo efficacy of Dioscin was assessed using a xenograft mouse model. Mechanistic investigations of Dioscin with ALDH1A3 were predicted by molecular docking and assessed through ALDH1A3 enzymatic activity and retinoic acid (RA) metabolism analyses. Results: ALDH1A3 expression correlates with early‐stage ovarian cancer progression. Genetic ablation of ALDH1A3 significantly suppressed cell proliferation, migration, and stemness properties. ALDH1A3 is significantly associated with ECM‐related genes in ovarian cancer. Dioscin exhibited an ALDH1A3‐dependent anti‐tumor effect by inhibiting ALDH1A3 enzymatic activity, disrupting RA metabolism, and downregulating the expression of stemness‐ and migration‐associated proteins (CD44 and MMP2). Furthermore, Dioscin effectively delays tumor growth without obvious signs of toxicity. Conclusion: Our study provides the first evidence that Dioscin inhibits ALDH1A3‐mediated RA metabolism and cancer stemness. Our data will further support its potential as a therapeutic agent for cancer treatment.
- 5 February 2026
- Published by Wiley in Phytotherapy Research
- Vol. 40 (4) , 1951-1969
Dioscin Suppresses Ovarian and Gastric Tumor Progression by Inhibiting ALDH1A3 ‐Mediated Retinoic Acid Metabolism and Cancer Stemness
Background: ALDH1A3 is a key factor associated with tumor stemness and chemotherapy resistance, making it a promising therapeutic target. Screening various compounds with potential inhibition of cancer stem cells led to the discovery of a naturally occurring Dioscin as a novel ALDH1A3 inhibitor. However, the precise mechanism underlying its action remains unexplored. Experimental Procedure: Immunohistochemical analysis of 90 ovarian serous tumor samples revealed the clinical significance of ALDH1A3 in tumor progression. TCGA data was used to identify genes highly correlated with ALDH1A3 in ovarian cancer. Using CRISPR/Cas9‐generated ALDH1A3 knockout (KO) cell lines, we investigated its oncogenic influence in ovarian and gastric cancers. The anti‐tumor effects of Dioscin were assessed through MTT, scratch, and 3D spheroid formation assays. In vivo efficacy of Dioscin was assessed using a xenograft mouse model. Mechanistic investigations of Dioscin with ALDH1A3 were predicted by molecular docking and assessed through ALDH1A3 enzymatic activity and retinoic acid (RA) metabolism analyses. Results: ALDH1A3 expression correlates with early‐stage ovarian cancer progression. Genetic ablation of ALDH1A3 significantly suppressed cell proliferation, migration, and stemness properties. ALDH1A3 is significantly associated with ECM‐related genes in ovarian cancer. Dioscin exhibited an ALDH1A3‐dependent anti‐tumor effect by inhibiting ALDH1A3 enzymatic activity, disrupting RA metabolism, and downregulating the expression of stemness‐ and migration‐associated proteins (CD44 and MMP2). Furthermore, Dioscin effectively delays tumor growth without obvious signs of toxicity. Conclusion: Our study provides the first evidence that Dioscin inhibits ALDH1A3‐mediated RA metabolism and cancer stemness. Our data will further support its potential as a therapeutic agent for cancer treatment.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.